CINECA IRIS Institutional Research Information System

ROMEI, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.080
EU - Europa 6.033
AS - Asia 4.751
SA - Sud America 742
AF - Africa 331
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 21.950
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.830
IT - Italia 2.224
SG - Singapore 1.503
CN - Cina 1.439
DE - Germania 1.205
SE - Svezia 876
HK - Hong Kong 857
BR - Brasile 627
GB - Regno Unito 355
BG - Bulgaria 314
VN - Vietnam 237
RU - Federazione Russa 206
CA - Canada 192
CI - Costa d'Avorio 190
IN - India 166
TR - Turchia 158
FI - Finlandia 155
AT - Austria 152
UA - Ucraina 112
FR - Francia 111
KR - Corea 102
NL - Olanda 69
SN - Senegal 64
JP - Giappone 61
CH - Svizzera 46
BD - Bangladesh 44
PL - Polonia 39
AR - Argentina 37
IQ - Iraq 33
EE - Estonia 32
BE - Belgio 31
MX - Messico 28
ZA - Sudafrica 26
PK - Pakistan 25
ES - Italia 23
EC - Ecuador 20
ID - Indonesia 20
CO - Colombia 17
MA - Marocco 17
SA - Arabia Saudita 15
GR - Grecia 14
CZ - Repubblica Ceca 13
UZ - Uzbekistan 12
IR - Iran 11
VE - Venezuela 11
TW - Taiwan 10
PE - Perù 9
CL - Cile 8
IL - Israele 8
JO - Giordania 8
LT - Lituania 8
RO - Romania 8
AU - Australia 7
IE - Irlanda 7
AZ - Azerbaigian 6
CR - Costa Rica 6
DZ - Algeria 6
EG - Egitto 6
KE - Kenya 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
MY - Malesia 5
PA - Panama 5
PT - Portogallo 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
BY - Bielorussia 4
HU - Ungheria 4
OM - Oman 4
RS - Serbia 4
SK - Slovacchia (Repubblica Slovacca) 4
AL - Albania 3
BH - Bahrain 3
EU - Europa 3
GT - Guatemala 3
KG - Kirghizistan 3
PS - Palestinian Territory 3
BJ - Benin 2
BO - Bolivia 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
ET - Etiopia 2
GE - Georgia 2
HN - Honduras 2
LK - Sri Lanka 2
PH - Filippine 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AI - Anguilla 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BZ - Belize 1
CM - Camerun 1
CY - Cipro 1
GA - Gabon 1
GD - Grenada 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
Totale 21.933
Salva come PNG Salva come JPEG
Città #
Ashburn 1.120
Dallas 865
Hong Kong 845
Fairfield 814
Singapore 799
Woodbridge 784
Ann Arbor 689
Chandler 614
Santa Clara 586
Houston 557
Seattle 340
Milan 335
Shanghai 329
Cambridge 317
Sofia 311
Beijing 297
Wilmington 271
New York 235
Abidjan 190
Boardman 163
Los Angeles 154
Serra 154
Princeton 143
Vienna 138
Ottawa 137
Munich 124
Jacksonville 121
Hefei 120
Lawrence 116
Rome 109
Medford 100
Pisa 100
Seoul 98
Florence 94
Frankfurt am Main 90
Des Moines 81
London 79
Nanjing 69
Izmir 66
Dearborn 65
Dakar 64
Istanbul 57
Dong Ket 56
Buffalo 55
Boulder 54
Bremen 52
Redondo Beach 51
Naples 49
Tokyo 47
Ho Chi Minh City 46
São Paulo 45
Redwood City 42
San Diego 41
Lancaster 38
Bern 37
Fuzhou 35
Helsinki 35
Washington 33
Bologna 32
Turku 32
Brussels 27
Düsseldorf 27
Genoa 27
Hanoi 26
San Jose 26
Ogden 24
Belo Horizonte 23
Grafing 23
Shenyang 23
Changsha 22
Phoenix 22
Redmond 22
Nanchang 21
Jüchen 20
Lucca 20
Rio de Janeiro 20
Council Bluffs 19
Tianjin 19
Warsaw 19
Mumbai 18
Baghdad 17
Kunming 17
Brooklyn 16
Johannesburg 16
Palermo 16
Pune 16
Quanzhou 16
Bengaluru 15
Columbus 15
Hangzhou 15
Hebei 15
Montreal 15
San Francisco 15
Toronto 15
Verona 15
Boston 14
Cascina 14
Parma 14
Poplar 14
Atlanta 13
Totale 14.271
Salva come PNG Salva come JPEG
Nome #
I CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE HANNO ORIGINE GENETICA INDIPENDENTE 1.092
L’ANALISI GENETICA DI CARCINOMI PAPILLARI E MIDOLLARI DELLA TIROIDE PRESENTI CONTEMPORANEAMENTE RIVELA LA LORO NATURA CASUALE 323
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 280
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 242
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 237
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 236
Risk of Differentiated Thyroid Carcinoma and Polymorphisms within the Susceptibility Cancer Region 8q24 231
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 220
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 215
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 214
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 213
Targeted Therapy in Thyroid Cancer: State of the Art 211
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 209
Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma 209
Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland 207
V804M RET MUTATION AND VANDETANIB RESPONSE IN METASTATIC MEDULLARY THYROID CANCER 207
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 206
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 200
A comprehensive meta-analysis of case-control association studies to evaluate polymorphisms associated with the risk of differentiated thyroid carcinoma 200
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 200
Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form. 196
RET point mutations in Thyroid Carcinoma 196
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 196
Multiple Endocrine Neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes 195
Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. 194
Next generation sequencing revealed RET or RAS mutation in medullary thyroid cancer that were negative at sanger sequencing 192
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: A 15-year median follow-up study 191
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 190
Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma 188
BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas 187
TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. 186
Strategies for single base gene editing in an immortalized human cell line by CRISPR/Cas9 technology 184
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 183
Serum bone Gla-protein (osteocalcin) in patients with bone metastases from thyroid cancer 182
Inherited variants in genes somatically mutated in thyroid cancer 182
Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. 180
GENETIC SCREENING OF RET CAN IDENTIFY NEW MUTATIONS EVEN AFTER 20 YEARS 179
Evidences that the polymorphism Pro-282-Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma 178
Polymorphisms within the RET proto-oncogene and risk of sporadic medullary thyroid carcinoma 178
Post-surgical follow-up of differentiated thyroid cancer. 171
Genome-wide association study on differentiated thyroid cancer. 169
Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience 169
The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans 168
Vandetanib and the predictive factors of durable response in locally advanced or metastatic medullary thyroid cancer: a single center experience. 168
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 166
Correction: Inherited variants in genes somatically mutated in thyroid cancer 163
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 163
Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma 163
Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze 162
Ruolo putativo di H4 come gene oncosoppressore nella patogenesi del carcinoma papillare della tiroide 160
RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma. 160
Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders 158
Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk 158
Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma 158
null 157
RET exon 11 (G691S) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population 157
Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years. 155
Mutazione V804M di RET nel carcinoma midollare della tiroide e risposta al trattamento con vandetanib 154
Pro64His (rs4644) polymorphism within galectin-3 is a risk factor of differentiated thyroid carcinoma and affects the transcriptome of thyrocytes engineered via CRISPR/Cas9 system 154
GENETIC LANDSCAPE OF SOMATIC MUTATIONS IN A LARGE COHORT OF SPORADIC MEDULLARY THYROID CARCINOMAS STUDIED BY NEXT GENERATION TARGETED SEQUENCING 153
A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New RET Germline Deletion 153
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 152
MON-524 Prospective Evaluation of Patients with Encapsulated Classical Variant of Papillary Thyroid Cancer and Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Have They A Similar Prognosis? 152
AFTER 20 YEARS, RET GENETIC SCREENING STILL INDENTIFIES NEW GERMILINE AND SOMATIC MUTATIONS 151
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 151
Genetic and clinical features of multiple endocrine neoplasia types 1 and 2 150
Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case-Control Studies. 149
Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas 149
Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: European comments to the guidelines of the American Thyroid Association 148
Prevalenza di mutazioni di BRAF e riarrangiamenti RET/PTC e TRK in una serie di carcinomi papillari della tiroide 146
null 146
Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma 146
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. 145
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 145
RET/PTC rearrangements in thyroid nodules: Studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults 144
New insights in the molecular signature of advanced medullary thyroid cancer: Evidence of a bad outcome of cases with double RET mutations 143
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 141
Clinical evolution of sporadic medullary thyroid carcinoma with biochemical incomplete response after initial treatment 140
Genetic signature of differentiated thyroid carcinoma susceptibility: a machine learning approach 139
Papillary Thyroid Carcinoma With Rare exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience 139
RET /PTC translocations and clinico-pathological features in human papillary thyroid carcinoma 138
L’ mRNA dei recettori per HGF e EGF (c-Met e EGFR) e’ iperespresso nei tumori papillari della tiroide 137
Predictive factors of short and long-term vandetanib response in locally advanced or metastatic medullary thyroid cancer: a single center experience 137
Il ciglitazone induce inibizione della crescita in cellule di carcinoma midollare della tiroide (TT) verosimilmente dovuta ad un aumentata espressione di PPAR gamma 136
RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases 136
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 135
Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis 135
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients 134
Chromosomal alterations in sporadic medullary thyroid carcinoma and correlation with outcome 133
Runs of homozygosity and inbreeding in thyroid cancer 133
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 133
Medullary thyroid carcinoma in children 132
Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma 132
Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series 131
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 131
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 130
Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1 128
CDKN1B V109G polymorphism a new prognostic factor in sporadic medullary thyroid carcinoma 128
NIS mRNA and protein expression in thyroid and non thyroid carcinoma 127
Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype 126
Totale 17.876
Salva come PNG Salva come JPEG
Categoria #
all - tutte 60.342
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 60.342
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021637 0 0 0 0 0 0 100 93 117 86 60 181
2021/20221.561 59 84 33 103 326 182 47 79 75 61 115 397
2022/20232.524 284 382 188 192 221 267 56 196 484 43 164 47
2023/20241.816 186 168 216 125 212 260 133 103 68 55 110 180
2024/20254.973 72 207 89 321 538 500 388 278 474 609 576 921
2025/20263.722 512 908 680 525 611 483 3 0 0 0 0 0
Totale 22.295